The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 12, 2025 in Geron Lawsuit

Core Viewpoint - Geron Corporation is facing a class action lawsuit due to allegations of misleading statements regarding the growth potential of its drug Rytelo (imetelstat), which led to a significant decline in stock price after disappointing financial results were announced [3][4]. Group 1: Allegations and Financial Impact - The class action is based on claims that Geron provided investors with overly optimistic expectations about Rytelo's launch and market potential, while downplaying risks related to monitoring requirements and competition [3]. - Following the announcement of fourth-quarter fiscal 2024 results, Geron reported that Rytelo's growth had flattened, attributing this to seasonality, competition, and lack of awareness, resulting in a stock price drop from $2.37 to $1.61, a decline of approximately 32.07% in one day [3]. Group 2: Class Action Details - The class period for the lawsuit is defined as February 28, 2024, to February 25, 2025, with a deadline for shareholders to register for participation set for May 12, 2025 [4]. - Shareholders who register will receive updates on the case's progress and can seek lead plaintiff status without any cost or obligation [4]. Group 3: Law Firm Background - The Gross Law Firm, which is leading the class action, is recognized for its commitment to protecting investors' rights against deceit and fraud, aiming to hold companies accountable for misleading practices [5].